Celldex Therapeutics (NASDAQ: CLDX) announced completion of enrollment in its global Phase 3 program evaluating barzolvolimab for chronic spontaneous urticaria ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE